Tokyo, Japan, June 23, 2023
Intas Pharmaceuticals Ltd. extends its congratulations to Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) on receiving approval from the Ministry of Health, Labour and Welfare for a partial change in its antineoplastic mitomycin C agents (Mitomycin Injection 2 mg and Mitomycin Injection 10 mg) by switching to a manufactured product in-licensed from Intas Pharmaceuticals Ltd.
In addition to this achievement, Kyowa Kirin’s topical ophthalmic mitomycin C agent (MITOMYCIN 2 mg for Ophthalmic Topical Use) received approval from MHLW on December 23, 2022, and has been listed on the NHI (National Health Insurance) drug price list as of May 24, 2023. Kyowa Kirin is actively making preparations for the successful launch of this product.
Intas Pharmaceuticals would like to commend Kyowa Kirin on its dedication to the health and well-being of individuals worldwide.
Intas B2B Team
